The OncoAlert Network 🚨
@oncoalert.bsky.social
3.2K followers 84 following 630 posts
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨 www.OncoAlert360.com
Posts Media Videos Starter Packs
oncoalert.bsky.social
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis

ascopubs.org/doi/abs/10.1...
oncoalert.bsky.social
🌍 Register now for the Global Forum in Prostate, Kidney & Bladder Cancer!
Join us live in Lisbon or ONLINE for this great hybrid meeting uniting experts from around the 🔗 Register today and be part of the global conversation: tinyurl.com/5y23u86w

🎟️ Early Bird Registration ends October 19!
Reposted by The OncoAlert Network 🚨
tumorijournal.bsky.social
💥Tumori Journal issue just out💥
Starting with an editorial by AIOM, the contents offer a broad overview of the most current and innovative topics in #oncology, covered by renowned researchers in the field.

Learn more journals.sagepub.com/toc/tmja/111...

#CanSky @oncoalert.bsky.social
oncoalert.bsky.social
The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.
oncoalert.bsky.social
A warm welcome to the 43rd Annual CFS, NOW VIRTUAL (LIVE OR ONLINE)
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG

A great 3 day conference for health care professionals focused on evidence-based, state-of-the-art cancer care. SIGN UP FOR FREE VIRTUAL REGISTRATION!
oncoalert.bsky.social
NOW Available on Demand: rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 library.mirrorsmed.org/index.php/ma...

What does it mean for clinical practice?
How should it guide treatment decisions?

📺 Join Neal Shore, MD @CURCMB & Alicia Morgans, MD @CaPsurvivorship @DanaFarber
oncoalert.bsky.social
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis

www.sciencedirect.com/science/arti...
oncoalert.bsky.social
NEWS FROM INDUSTRY: UPDATE ON TROPION-Breast02 #BreastCancer
Source European Pharmaceutical Review, Astrazeneca, Daiichi Sankyo

www.europeanpharmaceuticalreview.com/news/266702/...

The phase III TROPION-Breast02 trial showed that the ADC Datopotamab Deruxtecandlnk significantly improved OS & PFS
oncoalert.bsky.social
A warm welcome to the 43rd Annual CFS, NOW VIRTUAL (LIVE OR ONLINE) !!
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) tinyurl.com/3ak6zm6s

A great 3 day conference for health care professionals focused on evidence-based, state-of-the-art cancer care. SIGN UP FOR FREE VIRTUAL REGISTRATION!
oncoalert.bsky.social
Catch this case-based discussion on postoperative Biochemical Recurrence (BCR) in #ProstateCancer : Radiotherapy & Hormonal Therapy 👉 library.mirrorsmed.org/index.php/ma...

featuring
🔹 Prof. Bertrand Tombal
🔹 Dr. Vérane Achard
Now on Demand
oncoalert.bsky.social
See you in Berlin for #ESMO25!
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .

We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.
Reposted by The OncoAlert Network 🚨
flaviajacobs.bsky.social
So many news coming for #BreastCancer at #ESMO25! 🔥
oncoalert.bsky.social
The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin
Reposted by The OncoAlert Network 🚨
yukselurun.bsky.social
Proud of our rising star Coşkun and all colleagues. This meta-analysis on PARP inhibitors and thrombosis risk asks the right question for patients.
@oncoalert.bsky.social @myesmo.bsky.social @apccc.bsky.social @drchoueiri.bsky.social @neerajagarwal.bsky.social
Reposted by The OncoAlert Network 🚨
jmcgrane.bsky.social
🚨#RectalCancer Simply Oncology podcast today🚨
Richard Adams Returns!
🗣️IO revolution for MSI-H pts
🗣️Future directions
🗣️biggest wish EVER
LINK IN COMMENTS 👇
@oncoalert.bsky.social @icr.ac.uk @acpgbi.bsky.social @bowelcanceruk.bsky.social @velindrecc.bsky.social
Reposted by The OncoAlert Network 🚨
jmcgrane.bsky.social
Simply Oncology Podcast episode 26/09/25 -Cancer Vaccines

We talk to
@drlennardlee.bsky.social
& the mission to take cancer vaccines to the next level💉🦠

🎙️Using AI SUPERCOMPUTERS📟
🎙️⬇️5️⃣0️⃣% relapse

Link👇
@myesmo.bsky.social @cancerresearchuk.org @fighting-cancer.bsky.social @oncoalert.bsky.social
oncoalert.bsky.social
The OncoAlert #LungCancer Faculty, led by Dr.Hidehito Hironouchi 🇯🇵 as well as Dr Biagio Ricciuti 🇺🇸 and Dr. Gil Morgan🇺🇸 , have selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin 🇩🇪 Picked using a Delphi System to establish our picks.
oncoalert.bsky.social
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell #LungCancer : a systematic review and reconstructed individual patient data meta-analysis

www.thelancet.com/journals/lan...
oncoalert.bsky.social
The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin
oncoalert.bsky.social
rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 library.mirrorsmed.org/index.php/ma...

What does it mean for clinical practice?
How should it guide treatment decisions?

📺 Join Neal Shore, MD
@CURCMB
& Alicia Morgans, MD
@CaPsurvivorship
@DanaFarber
oncoalert.bsky.social
NEWS FROM INDUSTRY: DESTINY-BREAST05 & DESTINY-BREAST11 UPDATE
SOURCE: Astra Zeneca

www.astrazeneca.com/media-centre...

Data from both trials will be presented at #ESMO25 and shared with global regulators.
oncoalert.bsky.social
Clinical Perspective on Management of Key Adverse Events With Sacituzumab Govitecan

academic.oup.com/oncolo/advan...

Review highlights the incidence of key toxicities—neutropenia, diarrhea, fatigue, and alopecia—along with risk factors such as UGT1A1 polymorphisms and older age. #BreastCancer
oncoalert.bsky.social
rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 buff.ly/A8SymmS

What does it mean for clinical practice?
How should it guide treatment decisions?

📺 Join Neal Shore, MD
@CURCMB
& Alicia Morgans, MD
@CaPsurvivorship